Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

  • Technology appraisal guidance
  • TA887
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence